読み込み中
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
終値時点
$39.23
−$0.34 · -0.86%
時間外
$39.23
$0.00 · 0.00%
10月8日 16:15 ET
日中の時刻はETです。市場データは遅延する場合があります。
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
日中レンジ
現在 $39.23
52週レンジ
現在 $39.23
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
39
割高
センチメント
67
強気
リスク
35
中程度のリスク
モメンタム
72
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
日中レンジ
現在 $39.23
52週レンジ
現在 $39.23
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$53.10
上昇余地（35.36%）価格履歴は利用できません
最高：$66.00平均：$53.10最低：$36.00この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.22億0.01%2.3兆 USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM7445万0.10%785.63億 USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF3656.63万0.04%954億 USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO2647.34万0.19%142.49億 USD0.24%$353.47-0.53%
iShares Biotechnology ETFIBB2445.3万0.23%104.01億 USD0.44%$200.48-1.41%
Vanguard Russell 2000 ETFVTWO1717.14万0.09%180億 USD0.06%$112.1-0.10%
Schwab U.S. Small-Cap ETFSCHA1698.44万0.08%216.99億 USD0.03%$32.66+0.15%
iShares U.S. Pharmaceuticals ETFIHE1114.63万0.73%15.34億 USD0.37%$98.86-0.53%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
